Terms: = Germ cell tumor AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Treatment
860 results:
1. Transformation of idh-wildtype glioblastoma to gliosarcoma with features of osteosarcoma.
Sobczyk P; Sobstyl M; Acewicz A; Rosa J; Grabiec M; Grajkowska W
Folia Neuropathol; 2024; 62(1):96-101. PubMed ID: 38741436
[TBL] [Abstract] [Full Text] [Related]
2. Association of 5-aminolevulinic acid fluorescence guided resection with photodynamic therapy in recurrent glioblastoma: a matched cohort study.
da Silva EB; Vasquez MWM; de Almeida Teixeira BC; Neto MC; Sprenger F; Filho JLN; Almeida-Lopes L; Ramina R
Acta Neurochir (Wien); 2024 May; 166(1):212. PubMed ID: 38739282
[TBL] [Abstract] [Full Text] [Related]
3. Glioma.
Weller M; Wen PY; Chang SM; Dirven L; Lim M; Monje M; Reifenberger G
Nat Rev Dis Primers; 2024 May; 10(1):33. PubMed ID: 38724526
[TBL] [Abstract] [Full Text] [Related]
4. State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.
Schaff LR; Ioannou M; Geurts M; van den Bent MJ; Mellinghoff IK; Schreck KC
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e431450. PubMed ID: 38723228
[TBL] [Abstract] [Full Text] [Related]
5. Structural- and DTI- MRI enable automated prediction of idh Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach.
Yuan J; Siakallis L; Li HB; Brandner S; Zhang J; Li C; Mancini L; Bisdas S
BMC Med Imaging; 2024 May; 24(1):104. PubMed ID: 38702613
[TBL] [Abstract] [Full Text] [Related]
6. Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.
Liu J; Hu S; Jiang H; Cui Y
Front Immunol; 2024; 15():1369972. PubMed ID: 38690285
[TBL] [Abstract] [Full Text] [Related]
7. Association of Clinical, tumor, and treatment Characteristics With Seizure Control in Patients With
Bruno F; Pellerino A; Conti Nibali M; Pronello E; Cofano F; Rossi M; Levis M; Bertero L; Soffietti R; Cassoni P; Garbossa D; Bello L; Rudà R
Neurology; 2024 May; 102(10):e209352. PubMed ID: 38684041
[TBL] [Abstract] [Full Text] [Related]
8. Principles in the Management of Glioblastoma.
Roda D; Veiga P; Melo JB; Carreira IM; Ribeiro IP
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674436
[TBL] [Abstract] [Full Text] [Related]
9. Survival Outcome Prediction in Glioblastoma: Insights from MRI Radiomics.
Styliara EI; Astrakas LG; Alexiou G; Xydis VG; Zikou A; Kafritsas G; Voulgaris S; Argyropoulou MI
Curr Oncol; 2024 Apr; 31(4):2233-2243. PubMed ID: 38668068
[No Abstract] [Full Text] [Related]
10. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
[TBL] [Abstract] [Full Text] [Related]
11. GPR27 expression correlates with prognosis and tumor progression in gliomas.
Cai C; Hu L; Wu K; Liu Y
PeerJ; 2024; 12():e17024. PubMed ID: 38638156
[TBL] [Abstract] [Full Text] [Related]
12. DKK3 Expression in Glioblastoma: Correlations with Biomolecular Markers.
Caffo M; Casili G; Caruso G; Barresi V; Campolo M; Paterniti I; Minutoli L; Ius T; Esposito E
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612910
[TBL] [Abstract] [Full Text] [Related]
13. Shifting the landscape: The role of idh inhibitors in glioma cell fate.
Giacobetti SA; Fine HA
Cancer Cell; 2024 May; 42(5):741-743. PubMed ID: 38579726
[TBL] [Abstract] [Full Text] [Related]
14. Mutant idh inhibitors induce lineage differentiation in idh-mutant oligodendroglioma.
Spitzer A; Gritsch S; Nomura M; Jucht A; Fortin J; Raviram R; Weisman HR; Gonzalez Castro LN; Druck N; Chanoch-Myers R; Lee JJY; Mylvaganam R; Lee Servis R; Fung JM; Lee CK; Nagashima H; Miller JJ; Arrillaga-Romany I; Louis DN; Wakimoto H; Pisano W; Wen PY; Mak TW; Sanson M; Touat M; Landau DA; Ligon KL; Cahill DP; Suvà ML; Tirosh I
Cancer Cell; 2024 May; 42(5):904-914.e9. PubMed ID: 38579724
[TBL] [Abstract] [Full Text] [Related]
15. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
[TBL] [Abstract] [Full Text] [Related]
16. Oligodendroglioma, idh-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.
Sasaki H; Kitamura Y; Toda M; Hirose Y; Yoshida K
Brain Tumor Pathol; 2024 Apr; 41(2):43-49. PubMed ID: 38564040
[TBL] [Abstract] [Full Text] [Related]
17. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
18. REVOLUMAB: A phase II trial of nivolumab in recurrent idh mutant high-grade gliomas.
Picca A; Touat M; Belin L; Gourmelon C; Harlay V; Cuzzubbo S; Cohen-Jonathan Moyal E; Bronnimann C; Di Stefano AL; Laurent I; Lerond J; Carpentier C; Bielle F; Ducray F; Dehais C;
Eur J Cancer; 2024 May; 202():114034. PubMed ID: 38537315
[TBL] [Abstract] [Full Text] [Related]
19. Spatially Resolved Microglia/Macrophages in Recurrent Glioblastomas Overexpress Fatty Acid Metabolism and Phagocytic Genes.
Mistry AM; Daneshmand J; Seo SJ; Lehman NL; Miller DM; Goodin DA; Frieboes HB; Chen J; Masters A; Williams BJ; Yaddanapudi K
Curr Oncol; 2024 Feb; 31(3):1183-1194. PubMed ID: 38534921
[TBL] [Abstract] [Full Text] [Related]
20. Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers.
Straube C; Combs SE; Bernhardt D; Gempt J; Meyer B; Zimmer C; Schmidt-Graf F; Vajkoczy P; Grün A; Ehret F; Zips D; Kaul D
J Neurooncol; 2024 May; 168(1):49-56. PubMed ID: 38520571
[TBL] [Abstract] [Full Text] [Related]
[Next]
